| Drug NDC: | 44911-0452 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Animal Antigens |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Canary Feathers, Cat Hair, Cattle Epithelia, Chicken Feathers, Dog Epithelia, Duck Feathers, Gerbil Epithelia, Goat Epithelia, Goose Feathers, Guinea Pig Epithelia, Hamster Epithelia, Hog Epithelia, Horse Epithelia, Mouse Epithelia, Parakeet Feathers, Rabbit Epithelia, Rat Epithelia, Arsenicum Album, Nux Vomica, Phosphorus |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Energique, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ANAS PLATYRHYNCHOS FEATHER - 9 [hp_X]/mL ANSER ANSER FEATHER - 9 [hp_X]/mL ARSENIC TRIOXIDE - 12 [hp_X]/mL BOS TAURUS SKIN - 9 [hp_X]/mL CANIS LUPUS FAMILIARIS SKIN - 9 [hp_X]/mL CAPRA HIRCUS SKIN - 9 [hp_X]/mL CAVIA PORCELLUS SKIN - 9 [hp_X]/mL EQUUS CABALLUS SKIN - 9 [hp_X]/mL FELIS CATUS HAIR - 9 [hp_X]/mL GALLUS GALLUS FEATHER - 9 [hp_X]/mL Load more... MELOPSITTACUS UNDULATUS FEATHER - 9 [hp_X]/mL MERIONES UNGUICULATUS SKIN - 9 [hp_X]/mL MESOCRICETUS AURATUS SKIN - 9 [hp_X]/mL MUS MUSCULUS SKIN - 9 [hp_X]/mL ORYCTOLAGUS CUNICULUS SKIN - 9 [hp_X]/mL PHOSPHORUS - 12 [hp_X]/mL RATTUS NORVEGICUS SKIN - 9 [hp_X]/mL SERINUS CANARIA FEATHER - 9 [hp_X]/mL STRYCHNOS NUX-VOMICA SEED - 12 [hp_X]/mL SUS SCROFA SKIN - 9 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 18 Jul, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 23 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Energique, Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000185373 N0000175629 N0000184306 M0008280 M0000728 N0000185001 N0000185364 N0000185377 N0000185003 M0576325 M0515971 N0000185375 M0016962 M0516536 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 83B65P4796 15XI414745 S7V92P67HO 7J12CD6O9L X2W7CLE97T JLG9853E2P GM3H4U6QS8 88VZV9HGT4 1564HD0N96 1FCM16V0FV Load more... 1XY644QKWG 9WN2H714TG 3K873H631W 390AN9GB09 Z91WAU43WC 27YLU75U4W Y69HPD48AI 9EL3384IQY 269XH13919 3EM4VW6TQN |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Non-Standardized Feather Allergenic Extract [EPC] Non-Standardized Animal Skin Allergenic Extract [EPC] Standardized Animal Hair Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Feathers [CS] Allergens [CS] Dander [CS] Salivary Proteins and Peptides [CS] Plant Proteins [CS] Seed Storage Proteins [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Cell-mediated Immunity [PE] Cells Epidermal [EXT] Dander [CS] Feathers [CS] Increased Histamine Release [PE] Increased IgG Production [PE] Non-Standardized Animal Skin Allergenic Extract [EPC] Non-Standardized Feather Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] Plant Proteins [CS] Salivary Proteins and Peptides [CS] Seed Storage Proteins [CS] Standardized Animal Hair Allergenic Extract [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 44911-0452-1 | 30 mL in 1 BOTTLE, DROPPER (44911-0452-1) | 18 Jul, 2018 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.